This section synthesizes immunomodulatory strategies that (i) recalibrate the gut–liver axis and innate sensing in ALD–corticosteroids for sAH; epithelial‐targeted IL‐22/F‐652 to restore barrier defenses (Akkermansia, Reg3γ, α‐defensins) and limit endotoxemia; CRIg‐based augmentation of bacterial clearance; and IL‐1β blockade for β‐glucan/CLEC7A‐driven inflammation and (ii) reprogram macrophage polarization in MASLD, including inhibition of macrophage 17β‐HSD7 with nilotinib and dampening STING signaling via the RNF13–TRIM29 axis. Here, IL22 is linked to serum lipopolysaccharide activity.